GAITHERSBURG, Md.--Gene Logic said last week that with its Reads technology it has identified 2,513 genes associated with heart failure, renal disease, infertility, and other disorders, and 1,794 genes associated with mammalian toxicity. The 4,307 genes hold value as targets for new drugs or crop protection products or as markers to predict toxic effects of new compounds, the company claimed.
Earlier this month, UCB Research, a division of UCB Pharma, signed an agreement with Gene Logic for the development of a custom gene expression database for the discovery of new drugs for asthma and allergies. The companies will also collaborate to evaluate potential therapeutic targets resulting from the cooperation. Gene Logic will use its Reads technology and Affymetrix's GeneChip probe arrays to identify genes that are more or less active, or differentially expressed, in people with asthma and allergies than in healthy individuals.